Equity Research · Realized Position
Novo Nordisk
NVO · — · Pharmaceuticals · Metabolic Health
Rating
Realized — Stopped Out
Entry
$55.00
Exit
$39.00
Realized Return
−29.1%
Holding Period
Aug 2025 – Feb 2026
Quan Pham, Senior Analyst · M’Squared Capital Research · Closed 23 Feb 2026
We bought the GLP-1 leader believing the selloff was overdone. It wasn't — the thesis broke.
Summary
We entered Novo Nordisk at $55 on the view that share retention would hold and the drawdown was excessive. We were wrong. Competitive erosion from Lilly, a disappointing CagriSema readout, and US pricing pressure compounded, and we cut at $39 rather than defend a broken thesis.
Business Overview
Novo Nordisk leads GLP-1 diabetes and obesity therapeutics (Ozempic, Wegovy) in a market it helped create.
Investment Thesis
- 01
The thesis
Category leadership plus manufacturing scale should have defended both share and the multiple. That was the bet.
- 02
What broke it
CagriSema disappointed, Lilly's tirzepatide out-executed, and US drug-pricing and political pressure intensified — all at once.
- 03
Discipline over ego
When share retention, the core of the thesis, broke, we exited rather than average down into deterioration.
Valuation & Price Target
We stopped at $39, roughly −29%. The error was timing and an underestimate of competitive intensity; we do not fight a broken franchise thesis.
Catalysts
- The CagriSema trial disappointment
- Lilly share gains
- US drug-pricing pressure
Key Risks
- Competitive erosion of share
- Binary pipeline and trial risk
- Wrong entry timing
Bottom Line
A losing trade where exit discipline did its job. Realized −29.1%.
This note is the opinion of M’Squared Capital and is provided for informational purposes only. It is not investment advice, nor an offer or solicitation to buy or sell any security. Price targets and entry and exit levels reflect the firm’s proprietary views and realized transactions; they are not forecasts of future results. The firm may hold, add to, reduce, or close any position at any time without notice. Past performance is not indicative of future results.